Search Results - "Moes, Dirk J.A.R."

Autologous bone marrow-derived mesenchymal stromal cell therapy with early tacrolimus withdrawal: The randomized prospective, single-center, open-label TRITON study

Reinders, Marlies E.J. ^*, Groeneweg, Koen E., Hendriks, Sanne H., Bank, Jonna R., Dreyer, Geertje J., de Vries, Aiko P.J., van Pel, Melissa, Roelofs, Helene, Huurman, Volkert A.L., Meij, Paula, Moes, Dirk J.A.R., Fibbe, Willem E., Claas, Frans H.J., Roelen, Dave L., van Kooten, Cees, Kers, Jesper, Heidt, Sebastiaan, Rabelink, Ton J., de Fijter, Johan W.

Impact of alemtuzumab pharmacokinetics on T-cell dynamics, graft-versus-host disease and viral reactivation in patients receiving allogeneic stem cell transplantation with an alemtuzumab-based T-cell-depleted graft

Loeff, Floris C., van Egmond, Esther H.M., Moes, Dirk J.A.R., Wijnands, Charissa, Von Dem Borne, Peter A., Veelken, Hendrik, Falkenburg, J.H. Frederik, Jedema, Inge, Halkes, Constantijn J.M.

Severe COVID-19 in a renal transplant recipient: A focus on pharmacokinetics

Meziyerh, Soufian ^*, Zwart, Tom C., van Etten, Ronald W., Janson, Jeroen A., van Gelder, Teun, Alwayn, Ian P.J., de Fijter, Johan W., Reinders, Marlies E.J., Moes, Dirk J.A.R., de Vries, Aiko P.J.